What we do
Personalized and Precision Medicine can transform lives, but its potential benefits have not yet been fully realized.
Why is that? Because:
As a result, patients do not benefit from optimal treatment, with a health, societal and economic impact.
The From Testing to Targeted Treatments program (FT3) aims to respond to these challenges, through a co-creation approach, building with patients for patients.
Accelerate the benefits of precision medicine by generating better evidence, creating awareness and building the conditions for better access to targeted medicine in oncology and beyond.
How the From Testing to Targeted Treatments program is delivering on its promise
Landscape Mapping & Need Analysis
Understand the environment, barriers & map existing activities to inform strategic planning and identify synergies to build on.
Co-creation & Collaboration
Open collaboration globally to shape strategy and guide production for useful and impactful outcomes. Enable sustainable change by bringing together and supporting all stakeholder types in the whole precision medicine system.
Iteratively consult, test and improve solutions in real-life context, using FT3 community to reach a wider audience.
Integration & Optimization
Integrated & optimized global resources & solutions available to all stakeholders, bringing together learnings and best practices from across the precision medicine community.
Members have identified 5 strategic priorities that are being addressed through 3 co-creation working groups.
Patient and HCP Education and Awareness Working Group
Data and Evidence Working Group
Systemic Barriers & Opportunities Working Group
Transversal program priorities:
Build the value case for PM, starting with proven clinical areas, and raise awareness to increase support & resourcing
Build a world class governance and the foundation for trust, credibility, agile growth, and impact
Keep up to date with the latest developments from the FT3 Program
We don’t spam. Just key info at the right time.